First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Published Date: 02 Feb 2024

Out of 35 evaluable patients, 16 showed responses to cabotezantinib-pembrolizumab; one patient was still required.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma

4.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

5.

Lung cancer screening adherence rates decline annually after baseline screening


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot